DMT Therapy Developer Small Pharma Posts Financial Results, Reaffirms Potential Of Short-Acting Psychedelics

Biotech company Small Pharma Inc. (OTCQB: DMTTF), producer of short-acting psychedelic-assisted therapies for diverse mental health conditions, announced its financial results earlier this month for the fiscal year ended Feb. 28, 2022.

The company’s numbers up to closing date: 

  • Cash available totaled CA$40.7 million ($31.3 million).
  • Cash used in yearly business activities added up to CA$16.2 million ($12.4 million).
  • Operating expenses for the 12 months summed $18.1 million ($13.9 million).

The company is providing option grants for up to an aggregate of …

Full story available on Benzinga.com

More DMT Therapy Developer Small Pharma Posts Financial Results, Reaffirms Potential Of Short-Acting Psychedelics